Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment—A Cardio-Oncology Study

BACKGROUND: Abiraterone acetate (ABI) therapy improves overall survival in metastatic prostate cancer (PC) patients; however, this effect may be diminished by concurrent comorbidities. We aimed to evaluate the influence of pre-existing chronic diseases and concomitant medications on the course of AB...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilk, Michał, Waśko-Grabowska, Anna, Skoneczna, Iwona, Szmit, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047632/
https://www.ncbi.nlm.nih.gov/pubmed/33869068
http://dx.doi.org/10.3389/fonc.2021.664741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047632/
https://www.ncbi.nlm.nih.gov/pubmed/33869068
http://dx.doi.org/10.3389/fonc.2021.664741

Ejemplares similares